Videos
Frontline Treatment of Late-Stage EGFR+ Metastatic NSCLC: Optimizing an EGFR TKI Backbone or Adopting an Alternative EGFR/MET Bispecific Strategy?
04/14/2026
Round 1
Frontline EGFR+ mNSCLC: Does Evidence Favor Osimertinib Optimization or Alternative EGFR/MET Bispecific Approach?
Drs Lopes and Rodriguez debate the evidence supporting optimization of an osimertinib backbone vs an EGFR/MET bispecific approach for frontline treatment of EGFR+ mNSCLC.
Round 2
Efficacy vs Reality: Do Time Toxicity, Quality of Life, and Cost Tip the Frontline Decision?
Drs Lopes and Rodriguez debate the real-world trade-offs of frontline regimens, including time toxicity, quality of life, and cost of care.
Round 3
Beyond First Line: How Osimertinib- vs Amivantamab-Based Treatment Shapes What Comes Next
Drs Lopes and Rodriguez debate how frontline osimertinib- vs amivantamab-based strategies influence subsequent treatment sequencing and long-term management.
© 2026 HMP Global. This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
